Novel protein engineering strategy for creating highly receptor-selective mutant TNFs

Biochemical and Biophysical Research Communications

Volumn 388, Issue 4, 2009, Pages 667-671

  Nomura, Tetsuya ^a,b   Abe, Yasuhiro ^a   Kamada, Haruhiko ^a,b   Inoue, Masaki ^a   Kawara, Tomoyuki ^a,b   Arita, Shuhei ^a,b   Furuya, Takeshi ^a,b   Yoshioka, Yasuo ^b   Shibata, Hiroko ^a   Kayamuro, Hiroyuki ^a,b   Yamashita, Takuya ^a,b   Nagano, Kazuya ^a   Yoshikawa, Tomoaki ^a,b   Mukai, Yohei ^b   Nakagawa, Shinsaku ^b   Taniai, Madoka ^c   Ohta, Tsunetaka ^c   Tsunoda, Shin ichi ^a,b   Tsutsumi, Yasuo ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Gene shuffling; Phage display technique; Protein engineering; TNF receptor selective mutant; Tumor necrosis factor (TNF)

Indexed keywords

DNA; MUTANT PROTEIN; MUTANT TUMOR NECROSIS FACTOR R 1 20; MUTANT TUMOR NECROSIS FACTOR R 2 15; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; GEL FILTRATION CHROMATOGRAPHY; GENE LIBRARY; HUMAN; HUMAN CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; CELL LINE; DNA SHUFFLING; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE LIBRARY; PROTEIN ENGINEERING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

ESCHERICHIA COLI;

EID: 69949112332     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.08.052     Document Type: Article

References (18)

1. Wajant H., Pfizenmaier K., and Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 10 (2003) 45-65
2. Muto Y., Nouri-Aria K.T., Meager A., Alexander G.J., Eddleston A.L., and Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 2 (1988) 72-74
3. Feldmann M., and Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9 (2003) 1245-1250
4. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., and Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345 (2001) 1098-1104
5. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 (2002) 579-580
6. Weiss T., Grell M., Siemienski K., Muhlenbeck F., Durkop H., Pfizenmaier K., Scheurich P., and Wajant H. TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J. Immunol. 161 (1998) 3136-3142
7. Fotin-Mleczek M., Henkler F., Samel D., Reichwein M., Hausser A., Parmryd I., Scheurich P., Schmid J.A., and Wajant H. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J. Cell Sci. 115 (2002) 2757-2770
8. Van Ostade X., Tavernier J., and Fiers W. Structure-activity studies of human tumour necrosis factors. Protein Eng. 7 (1994) 5-22
9. Zhang X.M., Weber I., and Chen M.J. Site-directed mutational analysis of human tumor necrosis factor-alpha receptor binding site and structure-functional relationship. J. Biol. Chem. 267 (1992) 24069-24075
10. Yamagishi J., Kawashima H., Matsuo N., Ohue M., Yamayoshi M., Fukui T., Kotani H., Furuta R., Nakano K., and Yamada M. Mutational analysis of structure-activity relationships in human tumor necrosis factor-alpha. Protein Eng. 3 (1990) 713-719
11. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., Taniai M., Nomura T., Kayamuro H., Nabeshi H., Sugita T., Imai S., Nagano K., Yoshikawa T., Fujita T., Nakagawa S., Yamamoto A., Ohta T., Hayakawa T., Mayumi T., Vandenabeele P., Aggarwal B.B., Nakamura T., Yamagata Y., Tsunoda S., Kamada H., and Tsutsumi Y. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J. Biol. Chem. 283 (2008) 998-1007
12. Mukai Y., Shibata H., Nakamura T., Yoshioka Y., Abe Y., Nomura T., Taniai M., Ohta T., Ikemizu S., Nakagawa S., Tsunoda S., Kamada H., Yamagata Y., and Tsutsumi Y. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J. Mol. Biol. 385 (2009) 1221-1229
13. Shibata H., Yoshioka Y., Ohkawa A., Abe Y., Nomura T., Mukai Y., Nakagawa S., Taniai M., Ohta T., Mayumi T., Kamada H., Tsunoda S., and Tsutsumi Y. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-α in murine hepatitis models. Cytokine 44 (2008) 229-233
14. Abe Y., Yoshikawa T., Kamada H., Shibata H., Nomura T., Minowa K., Kayamuro H., Katayama K., Miyoshi H., Mukai Y., Yoshioka Y., Nakagawa S., Tsunoda S., and Tsutsumi Y. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J. Immunol. Methods 335 (2008) 71-78
15. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., Mukai Y., Shimizu T., Nakagawa S., Nagata S., and Mayumi T. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat. Biotechnol. 21 (2003) 546-552
16. Brunetti C.R., Paulose-Murphy M., Singh R., Qin J., Barrett J.W., Tardivel A., Schneider P., Essani K., and McFadden G. A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc. Natl. Acad. Sci. USA 100 (2003) 4831-4836
17. Tsutsumi Y., Kihira T., Tsunoda S., Kanamori T., Nakagawa S., and Mayumi T. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer 71 (1995) 963-968
18. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., Okamoto T., Taniai M., Kawamura M., Abe Y., Nakagawa S., Hayakawa T., Nagata S., Yamagata Y., Mayumi T., Kamada H., and Tsutsumi Y. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin. Cancer Res. 10 (2004) 8293-8300